1-DAY ACUVUE TRUEYE, NARAFILCON A
Report
- Report Number
- 1033553-2010-00059
- Event Type
- Injury
- Date Received
- September 13, 2010
- Date of Event
- July 30, 2010
- Report Date
- September 13, 2010
- Manufacturer
- VISTAKON
- Product Code
- LPL
- PMA / PMN Number
- K073485
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- JA
- Reporter Occupation
- NOT APPLICABLE
Narratives
DEVICE NOT RETURNED. NO EVALUATION WILL BE PERFORMED.
OUR (B)(4) AFFILIATE REPORTS A PT DEVELOPED IRITIS WHILE WEARING 1-DAY ACUVUE TRUEYE LENSES (NARAFILCON A). THE PT WAS SWITCHED FROM 1-DAY ACUVUE MOIST LENSES TO 1-DAY ACUVUE TRUEYE ON (B)(6)2010. THE PT WAS INITIALLY SEEN ON (B)(6)2010 FOR OU INJECTION. THE PT WAS DIAGNOSED WITH SPK OU AND IRITIS OD. CELLS WERE OBSERVED IN THE OD ANTERIOR CHAMBER AND THE PT HAD A CILIARY REACTION. THE PT WAS PRESCRIBED MEDS FOR THE OD ONLY, GATIFLOXACIN AND BESTRON Q2H SINCE AN INFECTION WAS SUSPECTED, TARIVID BID AND MYDRIN-P QD. AT THE TIME THE PT'S CORRECT VA OD WAS 1.2 (APPROX 20/20). THE PT RETURNED ON (B)(6)2010 AND THE SYMPTOMS WERE RESOLVED. THE LOT NUMBER OF THE 1-DAY TRUEYE LENSES OD WAS A RECALLED LOT. THE EYE CARE PROFESSIONAL (ECP) BELIEVES THIS INJURY WAS RELATED TO THE RECALLED PRODUCT. THE 1-DAY ACUVUE TRUEYE LENSES, NARAFILCON A, ARE NOT MARKETED IN THE U.S. THE PRODUCT WAS NOT RETURNED FOR EVALUATION. A REVIEW OF THE DEVICE HISTORY RECORD REVEALS THE FOLLOWING: THE BATCH RECORD DID NOT SHOW ANY ABNORMALITIES IN MONOMER AND SOLUTION TESTING. ALL PARAMETERS TESTED WERE WITHIN SPECIFICATION. ALL STERILIZATION REQUIREMENTS WERE SUCCESSFULLY COMPLETED. IF ADDITIONAL INFORMATION IS REC'D, WE WILL REPORT IT WITHIN 30 DAYS OF RECEIPT. MDR REPORTABLE EVENT TRENDS ARE REVIEWED QUARTERLY IN EXECUTIVE MANAGEMENT REVIEW MEETINGS.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 1 | 1-DAY ACUVUE TRUEYE, NARAFILCON A | SOFT CONTACT LENS | LPL | VISTAKON | NA | 4922510110 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 29 YR | Other |